Silvia Saboia Martins

Silvia Saboia Martins

Auto-generated profile, based on publicly available information

Silvia Saboia Martins

Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
MCMagdalena Cerdá
Magdalena Cerdá
CMChristine Mauro
Christine Mauro
AHAva Hamilton
Ava Hamilton
NLNatalie S. Levy
Natalie S. Levy
JSJulián Santaella-Tenorio
Julián Santaella-Tenorio
SMSilvia S. Martins
Silvia S. Martins
Marijuana is one of the world’s most widely used psychoactive substances. Approximately 183 million people, or 3.8% of the world’s population, used marijuana in 2015.1 Although occasional marijuana use is not associated with substantial problems, long-term, heavy use is linked to psychological and physical health concerns,2-4 lower educational attainment,5 decline in social class, unemployment,6,7 and motor vehicle crashes.8,9

10 January 2017 in JAMA
Verified
Journal Article
Open access
PDF file
QBQiana L. Brown
Qiana L. Brown
ASAaron L. Sarvet
Aaron L. Sarvet
DSDvora Shmulewitz
Dvora Shmulewitz
SMSilvia S. Martins
Silvia S. Martins
MWMelanie M. Wall
Melanie M. Wall
DHDeborah Hasin
Deborah Hasin
Between 2001 and 2013, marijuana use among US adults more than doubled, many states legalized marijuana use, and attitudes toward marijuana became more permissive.1 In aggregated 2007-2012 data, 3.9% of pregnant women and 7.6% of nonpregnant reproductive-aged women reported past-month marijuana use.2 Although the evidence is mixed, human and animal studies suggest that prenatal marijuana exposure may be associated with poor offspring outcomes (eg, low birth weight, impaired neurodevelopment).3 The American College of Obstetricians and Gynecologists recommends that pregnant women and women contemplating pregnancy be screened for and discouraged from using marijuana and other substances.4 Whether marijuana use has changed over time among pregnant and nonpregnant reproductive-aged women is unknown.

1 November 2015 in American Journal of Public Health
Verified
Journal Article
Closed access
SMSilvia S. Martins
Silvia S. Martins
LSLaura Sampson
Laura Sampson
MCMagdalena Cerdá
Magdalena Cerdá
SGSandro Galea
Sandro Galea
Background. Drug overdose is an important, yet an inadequately understood, public health problem. Global attention to unintentional drug overdose has been limited by comparison with the scope of the problem. There has been a substantial increase in drug overdose incidence and prevalence in several countries worldwide over the past decade, contributing to both increased costs and mortality. Objectives. The aim of this study was to systematically synthesize the peer-reviewed literature to document the global epidemiological profile of unintentional drug overdoses and the prevalence, time trends, mortality rates, and correlates of drug overdoses. We searched different combinations of Medical Subject Headings (MeSH) terms in PubMed for articles published from 1980 until July 2013, and we organized these results in tabular spreadsheets and compared them. We restricted the search to English-language articles that deal with unintentional overdose, focusing on 1 or more of the following key constructs: prevalence, time trends, mortality rates, and correlates. The term “overdose” as a MeSH major topic yielded 1076 publications. In addition, we searched the following combinations of nonmajor MeSH terms: “street drugs” and “overdose” yielded 180, “death” and “overdose” yielded 114, and “poisoning” and “drug users” yielded 17. There was some overlap among the searches. Based on the search and inclusion and exclusion criteria, we selected a total of 169 relevant articles for this article based on a close review of abstracts. Results. We found wide variability in lifetime prevalence of experiencing a nonfatal overdose or witnessing an overdose, and in mortality rates attributable to overdose. Lifetime prevalence of witnessed overdose among drug users (n = 17 samples) ranged from 50% to 96%, with a mean of 73.3%, a median of 70%, and a standard deviation of 14.1%. Lifetime prevalence of drug users personally experiencing a nonfatal overdose (n = 27 samples), ranged from 16.6% to 68.0% with a mean of 45.4%, a median of 47%, and a standard deviation of 14.4%. Population-based crude overdose mortality rates (n = 28 samples) ranged from 0.04 to 46.6 per 100 000 person-years. This range is likely attributable to the diversity in regions, time periods, and samples. Most studies on longitudinal trends of overdose death rates or overdose-related hospitalization rates showed increases in overdose death rates and in overdose-related hospitalization rates across time, which have led to peaks in these rates at the present time. An overall trend of increasing deaths from prescription opioid use and decreasing deaths from illicit drug use in the past several years has been noted across most of the literature. With the increase in prescription opioid overdose deaths, drug overdose is not just an urban problem: rural areas have seen an important increase in overdose deaths. Lastly, cocaine, prescription opioids, and heroin are the drugs most commonly associated with unintentional drug overdoses worldwide and the demographic and psychiatric correlates associated with unintentional drug overdoses are similar globally. Conclusions. There is a need to invest in research to understand the distinct determinants of prescription drug overdose worldwide. Several other countries need to collect in a systematic and continuous fashion such data on sales of prescription opioids and other prescription drugs, nonmedical use of prescription drugs, and hospitalization secondary to overdoses on prescription drugs. The sparse evidence on the environmental determinants of overdose suggests a need for research that will inform the types of environmental interventions we can use to prevent drug overdose. Methodological issues for future studies include enhancing data collection methods on unintentional fatal and nonfatal overdoses, and collecting more detailed information on drug use history, source of drug use (for prescription drugs), and demographic and psychiatric history characteristics of the individual who overdosed.


17 October 2011 in Psychological Medicine
Verified
Journal Article
Closed access
PDF file
SMS. S. Martins
S. S. Martins
MFM. C. Fenton
M. C. Fenton
KKK. M. Keyes
K. M. Keyes
CBC. Blanco
C. Blanco
HZH. Zhu
H. Zhu
CSC. L. Storr
C. L. Storr
Background: Non-medical use of prescription opioids represents a national public health concern of growing importance. Mood and anxiety disorders are highly associated with non-medical prescription opioid use. The authors examined longitudinal associations between non-medical prescription opioid use and opioid disorder due to non-medical opioid use and mood/anxiety disorders in a national sample, examining evidence for precipitation, self-medication and general shared vulnerability as pathways between disorders.Method: Data were drawn from face-to-face surveys of 34 653 adult participants in waves 1 and 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. Logistic regression models explored the temporal sequence and evidence for the hypothesized pathways.Results: Baseline lifetime non-medical prescription opioid use was associated with incidence of any mood disorder, major depressive disorder (MDD), bipolar disorder, any anxiety disorder and generalized anxiety disorder (GAD in wave 2, adjusted for baseline demographics, other substance use, and co-morbid mood/anxiety disorders). Lifetime opioid disorder was not associated with any incident mood/anxiety disorders. All baseline lifetime mood disorders and GAD were associated with incident non-medical prescription opioid use at follow-up, adjusted for demographics, co-morbid mood/anxiety disorders, and other substance use. Baseline lifetime mood disorders, MDD, dysthymia and panic disorder were associated with incident opioid disorder due to non-medical prescription opioid use at follow-up, adjusted for the same covariates.Conclusions: These results suggest that precipitation, self-medication as well as shared vulnerability are all viable pathways between non-medical prescription opioid use and opioid disorder due to non-medical opioid use and mood/anxiety disorders.

1 September 2015 in The Journal of Pediatrics
Verified
Journal Article
Closed access
MCMagdalena Cerdá
Magdalena Cerdá
JSJulián Santaella
Julián Santaella
BMBrandon D.L. Marshall
Brandon D.L. Marshall
JKJune H. Kim
June H. Kim
SMSilvia S. Martins
Silvia S. Martins